S. 5127 · 119th Congress · Taxation
Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026
- IntroducedJul 23, 2026 Done
- CommitteeReferred to Finance Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 407 wordsS. 5127 · Introduced in Senate · Jul 23, 2026
This Act may be cited as the Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026 .
(a) In general. Part III of subchapter B of chapter 1 of the Internal Revenue Code of 1986 is amended by inserting after section 139L the following new section: 139M. Clinical trial payments (a) In general Gross income shall not include any amount received by an individual as a qualified clinical trial payment. (b) Qualified clinical trial payment defined For purposes of this section, the term qualified clinical trial payment means any amount paid to an individual— (1) as compensation for participation by the individual or a dependent of the individual in an approved clinical trial, or (2) to reimburse or pay reasonable and necessary expenses incurred in connection with participation by the individual or a dependent of the individual in an approved clinical trial. (c) Other definitions For purposes of this section— (1) Approved clinical trial The term approved clinical trial has the meaning given such term in section 2709(d)(1) of the Public Health Service Act ( 42 U.S.C. 300gg–8(d)(1) ), determined by substituting disease or condition for life-threatening disease or condition . (2) Dependent The term dependent has the meaning given such term in section 152. .
(b) Clerical amendment. The table of sections for part III of subchapter B of chapter 1 of such Code is amended by inserting after the item relating to section 139L the following new item: Sec. 139M. Clinical trial payments. .
(c) Effective date. The amendments made by this section shall apply to amounts paid after December 31, 2025.
(a) In general. Notwithstanding any other provision of law, any amount received by an individual as a qualified clinical trial payment shall not be taken into account as income or resources for purposes of determining the eligibility of such individual (or any other individual) for benefits or assistance (or the amount or extent of benefits or assistance) under any Federal program or under any State or local program financed in whole or in part with Federal funds.
(b) Qualified clinical trial payment. For purposes of subsection (a), the term qualified clinical trial payment has the meaning given such term in section 139M(b) of the Internal Revenue Code of 1986 (as added by section 2 of this Act).
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
No lobbying filing on file names S. 5127.
Organizations that named S. 5127 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Jul 23, 2026Read twice and referred to the Committee on Finance.
- Jul 23, 2026Introduced in Senate